<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04792749</url>
  </required_header>
  <id_info>
    <org_study_id>MetforminEndometrialCancer</org_study_id>
    <nct_id>NCT04792749</nct_id>
  </id_info>
  <brief_title>Clinical Effects of Metformin on Fertility-sparing Treatment for Early Endometrial Cancer</brief_title>
  <official_title>Clinical Effects of Metformin on Fertility-sparing Treatment for Early Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the effects of metformin in addition to the&#xD;
      conventional progestin therapy in the fertility-sparing treatment of early stage endometrial&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment response rates</measure>
    <time_frame>3 months after the initiation of the treatment</time_frame>
    <description>Measurements of the primary lesion by the RECIST criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment response rates</measure>
    <time_frame>6 months after the initiation of the treatment</time_frame>
    <description>Measurements of the primary lesion by the RECIST criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment response rates</measure>
    <time_frame>9 months after the initiation of the treatment</time_frame>
    <description>Measurements of the primary lesion by the RECIST criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment response rates</measure>
    <time_frame>12 months after the initiation of the treatment</time_frame>
    <description>Measurements of the primary lesion by the RECIST criteria</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Endometrial Cancer Stage I</condition>
  <arm_group>
    <arm_group_label>Metformin treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who receive metformin in addition to progestin therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients who receive progestin therapy only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Patients are given 750, 1500, and 2000 mgs of metformin per os daily (dose increases weekly, then maintain at 2000 mgs) in addition to 500 mgs of medroxyprogesterone acetate per os daily and levonorgestrel-releasing intrauterine device for the treatment of early stage endometrial cancer.</description>
    <arm_group_label>Metformin treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Endometrial cancer radiologic International Federation of Obstetrics and Gynecology&#xD;
             (FIGO) stage IA patients&#xD;
&#xD;
          -  Endometrioid endometrial cancer patients&#xD;
&#xD;
          -  FIGO cellular differentiation grade 1 patients&#xD;
&#xD;
          -  Patients who wish to preserve fertility&#xD;
&#xD;
          -  Patients who understand that the recommended treatment of endometrial cancer is&#xD;
             surgical treatment even in early stages, but still wish to preserve fertility and&#xD;
             avoid surgical treatment&#xD;
&#xD;
          -  Patients who have good performance status (Eastern Cooperation Oncology Group (ECOG)&#xD;
             performance score equal to or greater than 3)&#xD;
&#xD;
          -  Patients who are not contraindicated to the progestin therapy&#xD;
&#xD;
          -  Patients who are not contraindicated to the use of metformin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have already received chemotherapeutic or radiotherapeutic treatments for&#xD;
             endometrial cancer&#xD;
&#xD;
          -  Patients whose disease is already advanced and not indicated for fertility-sparing&#xD;
             treatment&#xD;
&#xD;
          -  Patients whose tumor cellular differentiation grade is greater than FIGO grade 1&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong-Won Lee, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph Noh, M.D.</last_name>
    <phone>+82-10-9756-3249</phone>
    <email>joseph.noh@samsung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph J Noh, MD</last_name>
      <phone>+82-10-9756-3249</phone>
      <email>joseph.noh@samsung.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Jeong-Won Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Endometrial cancer</keyword>
  <keyword>Metformin</keyword>
  <keyword>Progestin</keyword>
  <keyword>Fertility-sparing treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

